Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Shares Sold by Fmr LLC

Fmr LLC trimmed its position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 17.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 792 shares of the company’s stock after selling 170 shares during the quarter. Fmr LLC’s holdings in Invesco Biotechnology & Genome ETF were worth $55,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Ashton Thomas Private Wealth LLC purchased a new position in Invesco Biotechnology & Genome ETF in the second quarter valued at approximately $26,000. UMB Bank n.a. purchased a new position in shares of Invesco Biotechnology & Genome ETF in the 2nd quarter valued at $31,000. Howe & Rusling Inc. purchased a new position in shares of Invesco Biotechnology & Genome ETF in the 3rd quarter valued at $31,000. Carnegie Investment Counsel acquired a new stake in Invesco Biotechnology & Genome ETF during the 3rd quarter worth $204,000. Finally, Creative Financial Designs Inc. ADV lifted its position in Invesco Biotechnology & Genome ETF by 5.6% in the third quarter. Creative Financial Designs Inc. ADV now owns 5,630 shares of the company’s stock valued at $393,000 after acquiring an additional 299 shares during the last quarter.

Invesco Biotechnology & Genome ETF Stock Performance

Shares of PBE stock opened at $67.46 on Wednesday. The stock’s 50-day moving average is $69.14 and its two-hundred day moving average is $68.64. Invesco Biotechnology & Genome ETF has a 1 year low of $59.32 and a 1 year high of $72.84. The firm has a market cap of $272.54 million, a price-to-earnings ratio of 17.12 and a beta of 0.88.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.